Partnership to support industry drive towards integrated end-to-end bioprocessing
Pall Corporation, the filtration, separation and purification specialist, has teamed up with BioSciencesCorp, to deliver cost-effective manufacturing strategies, and efficient upstream and downstream process equipment and facility design solutions for manufacturers.
“We are excited to partner with BioSciencesCorp to provide enabling technologies and services that support their customers mission-critical projects,” said Mario Philips, VP & General Manager at Pall Biotech. “Together, we can provide total solutions that today’s drug manufacturers need and make an impact where it matters most: with the patient.”
BioSciencesCorp is a consulting company providing novel biologics and biosimilars process know-how and regulatory experience from molecule selection to full commercialisation.
Customers benefit from small-company style, speed, and service and support from the initial modelling phases through implementation. The team is also available to help with critical aspects of process integrity, such as quality by design, process analytic technologies, and regulatory guidance.
“Starting from feasibility phases through to transfer and training activities, BioSciencesCorp was built to offer quality guidance and support to each customer,” said Daniel Chang, Executive Director and Founder of BioSciencesCorp. “Aligning with Pall Biotech deepens our ability to provide end-to-end, integrated solutions to customers from consultation through to clinical development and commercial manufacturing.”
This strategic partnership provides drug manufacturers with direct access to Pall Biotech bioreactors, mixing and storage product lines, single-use downstream technologies, consumables, and inter-unit operation connections.
Regardless of the type of project, customers also have the option to work with Pall service teams throughout process design and development to ensure process success.